BAJAJ BROKING
GlaxoSmithKline Pharmaceuticals Ltd. secured an income tax refund of ₹222.23 crore for FY 2022-23. The company reported a 37.8% YoY profit increase to ₹182.3 crore and a 60.1% EBITDA surge, driven by strong brand performance.
GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharma), a leading player in the global healthcare industry, announced on Tuesday, September 3, that it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23. The refund follows an order issued by the Income Tax Department under Section 143(3), which pertains to scrutiny assessments. The news was shared in a regulatory filing with the stock exchanges.
The announcement of the tax refund comes on the heels of a strong financial performance by GSK Pharma in the first quarter of the fiscal year 2024. The company reported a notable 37.8% year-on-year (YoY) increase in net profit, amounting to ₹182.3 crore. This marks a significant rise from the ₹132.3 crore profit reported in the same quarter of the previous fiscal year.
The company's revenue also showed positive momentum, growing by 7% to ₹814.7 crore, compared to ₹761.7 crore in the corresponding period of the preceding fiscal. This growth was supported by robust sales from key brands, including Calpol, Augmentin, and T-Bact, which continued to gain market share.
At the operating level, GSK Pharma's earnings before interest, tax, depreciation, and amortisation (EBITDA) surged by 60.1%, reaching ₹230.6 crore in the first quarter of the current fiscal year. This is a substantial increase from the ₹144 crore reported in the corresponding quarter of the previous fiscal year. The company's EBITDA margin also improved significantly, standing at 28.3% in the reporting quarter, up from 18.9% in the previous year's corresponding period.
The growth in EBITDA and the expansion of margins highlight the company's operational efficiency and its ability to capitalise on market opportunities.
GSK Pharma's continued success can be attributed to the strong performance of its key brands. Calpol, Augmentin, and T-Bact, among others, contributed to a 10% growth in sales. Additionally, the company's respiratory portfolio, including products like Nucala and Trelegy, achieved an impressive 57% growth, further expanding access to critical treatments for patients.
The receipt of the ₹222.23 crore income tax refund, coupled with the robust financial results for the first quarter of FY 2024, underscores GSK Pharma's strong market position and economic health. The company's focus on expanding its key brands and improving operational efficiency continues to drive its growth trajectory.
Disclaimer: Investments in the securities market are subject to market risk, read all related documents carefully before investing.
This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
For All Disclaimers Click Here: https://bit.ly/3Tcsfuc
Share this article:
Godrej Properties Acquires 53-Acre Land in Kolkata for ₹500 Crore
21 Nov, 2024 | 2 Min. read
GNFC Partners with INEOS to Build 600kt Acetic Acid Plant in Gujarat
21 Nov, 2024 | 2 Min. read
Adani Infra Launches Open Offer to Buy 26% Stake in PSP Projects
21 Nov, 2024 | 2 Min. read
UPL’s Advanta Secures $350M Investment from Alpha Wave Global
21 Nov, 2024 | 2 Min. read
Commodities Market Today | Crude Oil Drops, Gold Rises, Silver Falls in Market Moves
21 Nov, 2024 | 1 Min. read
Share Market Today | Gift Nifty Signals Weak Opening, Indian Markets May Consolidate
21 Nov, 2024 | 4 Min. read
Gold Rate Today | Gold Gains 0.9% to $2,653.50, Silver Drops 1%
21 Nov, 2024 | 2 Min. read
Know C2C Advanced Systems IPO Review, Objective & Applying Process
21 Nov, 2024 | 1 Min. read
Explore the List of Top Education Stocks in India
21 Nov, 2024 | 8 Min. read
What are Reverse Stock Splits: Meaning & Example
21 Nov, 2024 | 7 Min. read
How to Apply Under Shareholders' Quota in NTPC Green Energy IPO?
21 Nov, 2024 | 1 Min. read
What is Personal Finance? Meaning & Importance
21 Nov, 2024 | 4 Min. read
RBI Launches ULI: Transforming Loan Access
August 27, 2024 | 4 Min. read
Textile Sector in India
September 20, 2024 | 5 Min. read
List of IPOs with DRHPs Filed
November 30, 2023 | 3 Min. read
Aditya Birla Group
September 28, 2023 | 10 Min. read
Bajaj Housing Finance Ltd IPO: Things Smart Investors Need to Know
September 05, 2024 | 4 Min. read
Budget Stock Ideas 2024-2025 | Stocks to Buy Today
July 24, 2024 | 4 Min. read
IPO Eligibility Criteria : Full Details
March 15, 2024 | 6 Min. read
What Is the Lock-In Period in IPOs?
October 18, 2023 | 6 Min. read
Godfrey Phillips Announces 2:1 Bonus Shares
September 16, 2024 | 7 Min. read
Jindal Group- A Comprehensive Analysis
September 27, 2024 | 7 Min. read
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading